SMSei Muraoka

Sei Muraoka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sei Muraoka has a total of 207 co-authors. Here are the top co-authors by number of shared publications:

  • Toshihiro Nanki

    Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    13 shared publications
  • Kaichi Kaneko

    Division of Rheumatology, Department of Internal Medicine Toho University Sakura Medical Center Sakura Chiba Japan

    6 shared publications
  • Hiroshi Sato

    Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    5 shared publications
  • Keiko Koshiba

    Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    5 shared publications
  • Shotaro Masuoka

    Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    5 shared publications
  • Junko Nishio

    Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    4 shared publications

Latest Publications

  • Open Access

    Efficacy of romosozumab as sequential therapy for bisphosphonates in glucocorticoid-induced osteoporosis

    by Mai Kawazoe, Sei Muraoka, Zento Yamada, Wataru Hirose, Eri Watanabe, Junko Nishio, Toshihiro Nanki

    Glucocorticoids (GCs) affect the Wnt signaling pathway, which is a key mechanism underlying GC-induced osteoporosis (GIOP). The efficacy of romosozumab (ROMO), an antibody targeting sclerostin—an inhibitor of Wnt signaling—in treating GIOP remains unclear, as does its effectiveness when used sequentially after bisphosphonates (BP). In this prospective observational study, we aimed to evaluate the efficacy of ROMO as a sequential therapy following BP in patients with GIOP. Patients with rheumatic diseases receiving BP and GCs equivalent to 5 mg/d or more of prednisolone for at least 6 mo were enrolled and either switched from BP to ROMO (ROMO group) or continued on BP (BP group). BMD of the LS (L2-4), FN, and TH were measured every 6 mo, and bone turnover markers were assessed every 3 mo. Six patients in the ROMO group and 22 in the BP group were analyzed. Patients in the ROMO group were significantly older (78.5 vs 64.5 yr), had a higher history of vertebral fractures, had lower baseline BMD of the FN and TH, and tended to receive higher GC dose (8.0 mg vs 5.0 mg) compared with the BP group. The median (25th-75th percentile) BMD percent changes at 12 mo were numerically higher in the ROMO group compared to the BP group (LS 2.6 [0.8-3.4] % vs 1.6 [−1.9−4.3] %; FN 1.4 [−0.5−5.4] % vs 1.0 [−4.7−5.6] %; TH: 1.1 [−7.6−6.5] % vs −1.8 [−6.4−1.8] %), although their differences were not statistically significant. One new vertebral fracture was observed in the BP group, and 1 patient in the ROMO group experienced a cerebral infarction. These findings suggest that ROMO may be an effective sequential therapy for BP in patients with GIOP.

  • Open Access

    Exploratory analysis of early changes in peripheral immune cell proportions and clinical response following methotrexate and biologic treatment in rheumatoid arthritis

    by Sei Muraoka, Tomohiro Yamada, Nobuyuki Yasuda, Jungo Kakuta, Hiroshi Sato, Satoshi Mizutani, Makoto Kaburaki, Toshio Imai, Toshihiro Nanki

    Sei Muraoka, M.D., Ph.D., Tomohiro Yamada, Ph.D., Nobuyuki Yasuda, Ph.D., Jungo Kakuta, M.S., Hiroshi Sato, M.D., Ph.D., Satoshi Mizutani, M.D., Ph.D., Makoto Kaburaki, M.D., Ph.D., Toshio Imai, Ph.D., Toshihiro Nanki, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2025.0182

  • Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial

    by Mai Kawazoe, Shotaro Masuoka, Kaichi Kaneko, Zento Yamada, Karin Furukawa, Eri Watanabe, Keiko Koshiba, Soichi Yamada, Sei Muraoka, Hiroshi Sato, et al.

    Summary The efficacy of romosozumab (ROMO) in treating glucocorticoid-induced osteoporosis remains unclear. This randomized clinical trial demonstrated that in patients initiating glucocorticoid therapy, a treatment regimen of 12 months of ROMO followed by 24 months of denosumab (DMAb) was effective compared to either 36 months of DMAb or bisphosphonate monotherapy. Purpose The efficacy of romosozumab (ROMO), an antibody against sclerostin—an inhibitor of Wnt signaling—in the treatment of glucocorticoid-induced osteoporosis remains uncertain, particularly regarding the sequential use of ROMO and denosumab (DMAb). This study aimed to compare the long-term efficacy of 12 months of ROMO followed by 24 months of DMAb (ROMO-DMAb) to 36 months of DMAb or bisphosphonates (BP) alone. Methods Patients with rheumatic diseases who had not previously received osteoporosis drugs and were newly treated with prednisolone ≥ 15 mg/day were randomly assigned to receive ROMO (ROMO-DMAb group), DMAb, or risedronate. Over a 36-month period, we measured bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip every 6 months. Results Thirty-nine patients (median [interquartile ranges] age 72.0 [67.3 – 78.8] years; 69.2% women; prednisolone dose 20.0 [15.0 – 50.0] mg/day) were enrolled. The median percent change in lumbar spine BMD from baseline at 36 months was greatest in the ROMO-DMAb group (ROMO-DMAb; 11.3 [6.8 – 13.8] %, DMAb; 9.4 [4.7 – 13.5] %, BP; 2.1 [-1.3 – 6.8] %). The changes in the femoral neck and total hip were similar between the ROMO-DMAb and DMAb groups, and the increases were much smaller than that in the lumbar spine. Serum levels of total type I procollagen-N-propeptide and tartrate-resistant acid phosphatase-5b decreased in all groups from month 3. Conclusion Sequential treatment with ROMO followed by DMAb increased lumbar spine BMD more than DMAb or BP alone up to 36 months, demonstrating the efficacy of this treatment strategy.


  • Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study

    by Yohei Kirino, Ayaka Maeda, Kana Higashitani, Nobuyuki Horita, Tomoyuki Asano, Kiyoshi Migita, Yoshikazu Motomura, Ryo Rokutanda, Daisuke Kobayashi, Masao Tamura, et al.


  • Anti-SRP antibody-positive polymyositis complicated by neuromyelitis optica spectrum disorder: a case report and literature review

    by Eisuke Tanaka, Mai Kawazoe, Shotaro Masuoka, Yudai Aikawa, Takashi Tanaka, Keiko Koshiba, Zento Yamada, Risa Wakiya, Eri Watanabe, Sei Muraoka, et al.

    Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory demyelinating disease primarily affecting the optic nerves and spinal cord. Polymyositis (PM) is an idiopathic inflammatory myopathy characterized by proximal muscle weakness. The anti-signal recognition particle (SRP) antibody is a myositis-specific autoantibody. We herein present a case of anti-SRP antibody-positive PM that developed 6 years after the onset of NMOSD. A 52-year-old woman was diagnosed with NMOSD 6 years previously based on left visual disturbance, a high signal intensity and contrast enhancement of the optic nerve on short τ inversion recovery (STIR)-magnetic resonance imaging (MRI), and anti-aquaporin 4 antibody positivity. She received methylprednisolone pulse therapy followed by oral prednisolone (PSL) at a starting dose of 40 mg daily. Three years later, due to recurrent numbness in the left lower limb and difficulty in reducing the PSL dose to ≤10 mg/day, satralizumab was initiated. At 52 years old, she developed myalgia and muscle weakness in both thighs. PM was diagnosed based on an elevated serum creatine kinase level, anti-SRP antibody positivity, high signal intensities in the right triceps and bilateral adductor muscles on STIR-MRI, and muscle biopsy findings. Treatment with high-dose PSL and tacrolimus markedly attenuated her symptoms. Satralizumab was continued for NMOSD stabilisation. Previous studies reported the coexistence of NMOSD and autoimmune diseases; however, NMOSD with PM/DM is rare. We described a case of NMOSD with anti-SRP antibody-positive PM and provided a literature review.

  • Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy

    by Mai Kawazoe, Kaichi Kaneko, Shotaro Masuoka, Soichi Yamada, Zento Yamada, Sei Muraoka, Karin Furukawa, Hiroshi Sato, Eri Watanabe, Keiko Koshiba, et al.

    Context: Wnt/β-catenin signaling pathway is one of the pathogenic mechanisms of glucocorticoid-induced osteoporosis (GIOP). We previously reported the potential of inhibiting sclerostin as a treatment for GIOP. Objective: To compare the efficacy of romosozumab (ROMO), a monoclonal antibody against sclerostin, with existing therapy for GIOP. Methods: Patients with rheumatic diseases who had not previously received treatment for osteoporosis and were newly treated with prednisolone 15 mg/day or more were randomly assigned to receive ROMO, denosumab (DMAb), or bisphosphonates (BP). After the initiation of glucocorticoid therapy, we measured the bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip every 6 months and bone turnover markers every 3 months for 12 months. Results: Eleven patients were assigned to the ROMO group, 14 to the DMAb group, and 14 to the BP group. The median [25th to 75th percentile] percent change in lumbar spine BMD from baseline at 12 months was the greatest in the ROMO group (ROMO: 8.6 [3.1-12.4]%, DMAb: 3.3 [1.5-6.2]%, BP: −0.4 [−3.4-1.1]%). Among bone formation markers, serum levels of bone alkaline phosphatase were slightly elevated in the ROMO group, whereas those of N-terminal propeptide of type I procollagen and osteocalcin decreased in all 3 groups; however, these changes were smaller in the ROMO group. Serum levels of bone resorption markers and a urine bone quality marker decreased in all groups. Conclusion: Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients, suggesting that ROMO is effective for GIOP. Clinical trial number: UMIN000037239


  • Open Access

    Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis

    by Sei Muraoka, William D. Brodie, Megan N. Mattichak, Mikel Gurrea‐Rubio, Yuzo Ikari, Caroline Foster, M. Asif Amin, Neha Khanna, Hafsa Amin, Phillip L. Campbell, et al.

    Objective: Systemic sclerosis (SSc) is an autoimmune multisystem disease with poorly understood pathogenesis and ineffective treatment options. Soluble CD13 (sCD13), generated by the cleavage of cell surface CD13 via matrix metalloproteinase 14 (MMP14), signals through the bradykinin receptor B1 (B1R) to elicit pro‐inflammatory, pro‐arthritic, and pro‐angiogenic responses. In this study, we explored the antifibrotic potential of targeting the sCD13‐B1R axis in SSc.Methods: The expression of CD13, B1R, and MMP14 was examined in SSc skin and explanted dermal fibroblasts. The efficacy of B1R antagonists in the inhibition on fibrosis was determined in vitro and in vivo.Results: Expression of the genes for CD13, B1R, and MMP14 was elevated in skin biopsies from patients with diffuse cutaneous (dc) SSc. Notably, single‐cell analysis of SSc skin biopsies revealed the highest BDKRB1 expression in COL8A1‐positive myofibroblasts, a population exclusively seen in SSc. Transforming growth factor beta (TGFβ) induced the expression of BDKRB1 and production of sCD13 by dcSSc skin fibroblasts. Treatment of dcSSc fibroblasts with sCD13 promoted fibrotic gene expression, signaling, cell proliferation, migration, and gel contraction. The pro‐fibrotic responses of sCD13 or TGFβ were prevented by a B1R antagonist. Mice lacking Cd13 or Bdkrb1 were resistant to bleomycin‐induced skin fibrosis and inflammation. Pharmacological B1R inhibition had a comparable antifibrotic effect.Conclusion: These results are the first to demonstrate a key role for sCD13 in SSc skin fibrosis and suggest that targeting the sCD13‐B1R signaling axis is a promising novel therapeutic approach for SSc. image


  • Open Access

    Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1

    by Pei-Suen Tsou, Chenyang Lu, Mikel Gurrea-Rubio, Sei Muraoka, Phillip L. Campbell, Qi Wu, Ellen N. Model, Matthew E. Lind, Sirapa Vichaikul, Megan N. Mattichak, et al.

    CD13, an ectoenzyme on myeloid and stromal cells, also circulates as a shed, soluble protein (sCD13) with powerful chemoattractant, angiogenic, and arthritogenic properties, which require engagement of a G protein–coupled receptor (GPCR). Here we identify the GPCR that mediates sCD13 arthritogenic actions as the bradykinin receptor B1 (B1R). Immunofluorescence and immunoblotting verified high expression of B1R in rheumatoid arthritis (RA) synovial tissue and fibroblast-like synoviocytes (FLSs), and demonstrated binding of sCD13 to B1R. Chemotaxis, and phosphorylation of Erk1/2, induced by sCD13, were inhibited by B1R antagonists. In ex vivo RA synovial tissue organ cultures, a B1R antagonist reduced secretion of inflammatory cytokines. Several mouse arthritis models, including serum transfer, antigen-induced, and local innate immune stimulation arthritis models, were attenuated in Cd13–/– and B1R–/– mice and were alleviated by B1R antagonism. These results establish a CD13/B1R axis in the pathogenesis of inflammatory arthritis and identify B1R as a compelling therapeutic target in RA and potentially other inflammatory diseases.


  • Open Access

    Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma

    by Sirapa Vichaikul, Mikel Gurrea-Rubio, M. Asif Amin, Phillip L. Campbell, Qi Wu, Megan N. Mattichak, William D. Brodie, Pamela J. Palisoc, Mustafa Ali, Sei Muraoka, et al.

    Binding of the bromodomain and extraterminal domain proteins (BETs) to acetylated histone residues is critical for gene transcription. We sought to determine the antifibrotic efficacy and potential mechanisms of BET inhibition in systemic sclerosis (SSc). Blockade of BETs was done using a pan-BET inhibitor, JQ1; BRD2 inhibitor, BIC1; or BRD4 inhibitors AZD5153 or ARV825. BET inhibition, specifically BRD4 blockade, showed antifibrotic effects in an animal model of SSc and in patient-derived diffuse cutaneous SSc (dcSSc) fibroblasts. Transcriptome analysis of JQ1-treated dcSSc fibroblasts revealed differentially expressed genes related to extracellular matrix, cell cycle, and calcium (Ca 2+ ) signaling. The antifibrotic effect of BRD4 inhibition was mediated at least in part by downregulation of Ca 2+ /calmodulin–dependent protein kinase II α and reduction of intracellular Ca 2+ concentrations. On the basis of these results, we propose targeting Ca 2+ pathways or BRD4 as potentially novel therapeutic approaches for progressive tissue fibrosis.